Tabberer, Maggie
von Maltzahn, Robyn
Bacci, Elizabeth D.
Karn, Hayley
Hsieh, Ray
Howell, Timothy A.
Bailes, Zelie
Fowler, Andrew
Lee, Laurie
Murray, Lindsey T.
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 9 November 2020
Accepted: 30 June 2021
First Online: 10 October 2021
Declarations
:
: In Phase 1, all recruitment procedures complied with current Health Insurance Portability and Accountability Act (HIPAA) regulations. Evidera obtained ethical approval from the Ethics and Independent Review Services for the study protocol. Prior to the interview, each participant signed an informed consent form. In Phase 2, Institutional Review Board (IRB) approval was obtained to comply with human patients’ research requirements prior to initiation of patient recruitment or administration of measures as part of each clinical trial (205832, 205715). No additional ethics committee or IRB approval was required for this secondary data analysis.
: Not applicable.
: RvM, ZB, and AF are employees of and hold stock in GlaxoSmithKline (GSK). EDB, TAH, HK, and RH are employees of Evidera. Evidera provides consulting and other research services to pharmaceutical, device, government and non-government organizations. As Evidera employees, they work with a variety of companies and organizations and are expressly prohibited from receiving any payment or honoraria directly from these organizations for services rendered. LTM was a former employee of Evidera. MT and LL were former employees of GSK at the time this work was conducted and holds stocks or shares in GSK.